Anti-HER2 monoclonal antibody that inhibits HER2 signaling and mediates antibody-dependent cellular cytotoxicity (ADCC).
Humanized anti-HER2 monoclonal antibody that binds HER2 (ErbB2) on tumor cells, inhibits HER2-driven signaling and proliferation, and induces antibody-dependent cellular cytotoxicity via Fc gamma receptor–bearing effector cells.
YES
DIRECT
Trastuzumab binds HER2 on tumor cells and its Fc engages Fcγ receptor–bearing effector cells (e.g., NK cells) to trigger antibody-dependent cellular cytotoxicity, killing HER2+ cells; it also inhibits HER2 signaling.
Autologous CD8+ and CD4+ T cells genetically engineered to express a high-affinity T-cell receptor specific for the KRAS G12V peptide presented by HLA-A*11:01, designed to recognize and kill KRAS G12V–positive tumor cells (adoptive cellular therapy).
Autologous CD8+ and CD4+ T cells engineered to express a high-affinity TCR specific for the KRAS G12V peptide presented by HLA-A*11:01. Upon HLA-restricted recognition of KRAS G12V on tumor cells, the transgenic TCR triggers T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxicity, selectively eliminating KRAS G12V–positive tumor cells.
YES
DIRECT
Engineered TCR T cells recognize the HLA-A*11:01–presented KRAS G12V peptide on tumor cells, activating cytotoxic T cells to kill via perforin/granzyme-mediated apoptosis (± Fas/FasL).
An antibody–drug conjugate (ADC) consisting of a humanized anti–Trop-2 monoclonal antibody linked to SN-38 (the active metabolite of irinotecan), a topoisomerase I inhibitor. After binding Trop-2 on tumor cells, the ADC is internalized and releases SN-38 to inhibit topoisomerase I, leading to DNA damage and apoptosis. Administered IV at 10 mg/kg on days 1 and 8 of a 21-day cycle.
Humanized anti–Trop-2 monoclonal antibody linked to SN-38 (topoisomerase I inhibitor). After binding Trop-2 on tumor cells, the ADC is internalized and releases SN-38, which stabilizes Topo I–DNA complexes, causing DNA damage, S-phase arrest, and apoptosis; membrane-permeable SN-38 can produce a bystander effect.
YES
DIRECT
After ADC delivery to Trop-2–positive cells, the SN-38 payload inhibits topoisomerase I by stabilizing Topo I–DNA complexes, causing DNA damage, S-phase arrest, and apoptosis (with possible bystander effect).
Anti-CD20 monoclonal antibody that depletes B cells via CDC, ADCC, and apoptosis.
Anti-CD20 chimeric monoclonal antibody that binds CD20 on B cells and depletes them via complement-dependent cytotoxicity (CDC), Fc-mediated antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP), and direct induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and triggers complement-dependent cytotoxicity and Fc-mediated ADCC/ADCP by immune effector cells; CD20 ligation can also induce apoptosis.
Investigational anti-HIV monoclonal antibody intended to directly target HIV (likely the envelope) to help control viremia via neutralization and immune effector engagement.
Investigational anti-HIV monoclonal antibody that binds the viral envelope to neutralize virions and block entry, while engaging Fc-mediated effector functions (e.g., ADCC/ADCP/CDC) to help clear virus and infected cells, thereby reducing viremia.
YES
DIRECT
The anti-Env antibody binds HIV-1 Env on infected cells and engages Fc effector functions—NK cell–mediated ADCC, macrophage ADCP, and complement-dependent cytotoxicity—leading to killing/clearance of Env-expressing cells.